Prevention and treatment of renal osteodystrophy in children with chronic renal insufficiency and end-stage renal disease

Seminars in Nephrology

Volumn 21, Issue 5, 2001, Pages 441-450

  Sanchez, Cheryl P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D;

AGE; BONE LESION; CHILD; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; HORMONE INHIBITION; HUMAN; HUMAN TISSUE; PARATHYROIDECTOMY; PRIORITY JOURNAL; PROPHYLAXIS; RENAL OSTEODYSTROPHY; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION;

EID: 0034844077     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.24938     Document Type: Review

References (73)

1. Pathogenesis of secondary hyperparathyroidism
2. Growth of long bones in renal failure: Roles of hyperparathyroidism, growth hormone and calcitriol
3. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism
4. Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency
5. Bone histology in incipient and advanced renal failure
6. Phosphorus restriction prevents parathyroid gland growth
7. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency
8. 3 deficiency and renal osteodystrophy: Should its well-accepted pathogenetic role in secondary hyperparathyroidism lead to its systematic preventive therapeutic use?
9. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease
10. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat
11. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol
12. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism
13. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure
14. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients
15. The parathyroid calcium receptor: A novel therapeutic target for treating hyperparathyroidism
16. Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia
17. Association of decreased calcium-sensing receptor expression with proliferation of prathyroid cells in secondary hyperparathyroidism
18. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure
19. A comparison of parathyroid-gland function in hemodialyis patients with different forms of renal osteodystrophy
20. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD
21. Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients
22. Early diagnosis of juvenile renal osteodystrophy
23. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
24. Renal bone diseases in children with chronic renal failure
25. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia
26. A novel mechanism for skeletal resistance in uremia
27. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uremic rats
28. The treatment of uremic hyperphosphatemia with calcium acetate and calcium carbonate: A comparative study
29. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients
30. RenaGel, a nonabsorbed calcium-and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone
31. New phosphate binding agents: Ferric compounds
32. Citrate: A major factor in the toxicity of orally administered aluminum compounds
33. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
34. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis
35. 3 in childhood renal osteodystrophy
36. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure
37. 25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: Beneficial effect on linear growth velocity
38. Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)
39. Long-term low-dose calcitriol treatment in predialysis chronic renal failure: Can it prevent hyperparathyroid bone disease?
40. Calcitriol and calcium carbonate therapy in early chronic renal failure
41. 3 administration in moderate renal failure: A prospective double-blind trial
42. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure
43. Daily but not pulse calcitriol therapy improves growth in experimental uremia
44. 3 have different effects on growth plate chrondrocytes in vitro
45. Role of 1,25-dihydrocholecalciferol in growth plate cartilage: Inhibition of terminal differentiation of chondrocytes in vitro and in vivo
46. 3 on cartilage growth in neonatal mice
47. Alphacalcidol oral pulses normalize uremic hyperparathyroidism prior to dialysis
48. 3 treatment of nondialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function
49. A prospective, double-blind study of growth failure in children with chornic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol
50. Controlled trial of 1[alpha]-hydrocholecalciferol in chronic renal failure
51. Is 1,25-dihydroxy-cholecalciferol harmful to renal function in patients with chronic renal failure?
52. Marked suppression of secondary hyperparathyroidism by IV administration of 1,25-dihydroxycholecalciferol in uremic patients
53. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone
54. 3 therapy in children treated with peritoneal dialysis
55. Intravenous versus oral calcitriol therapy in renal osteodystrophy: Results of a prospective, pulsed and dose-comparable study
56. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients
57. Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration
58. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
59. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD
60. 3
61. Pulse oral versus pulse intraperitoneal calcitriol: A comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients
62. 'Pulse' oral calcitriol in uremic patients: Rapid modification of parathyroid response to calcium
63. A controlled trial of early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients
64. The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism
65. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD
66. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism
67. Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol
68. 2) therapy for secondary hyperparathyroidism
69. Y: Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism
70. 2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats
71. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism
72. NPS R-568 halts or reverses osteitis fibrosa in uremic rats
73. Calcimimetic NPS-R568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism